RT Journal Article
SR Electronic
T1 Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-qPCR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20067348
DO 10.1101/2020.04.17.20067348
A1 Smyrlaki, Ioanna
A1 Ekman, Martin
A1 Vondracek, Martin
A1 Papanicolaou, Natali
A1 Lentini, Antonio
A1 Aarum, Johan
A1 Muradrasoli, Shaman
A1 Albert, Jan
A1 Högberg, Björn
A1 Reinius, Björn
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.17.20067348.abstract
AB Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The most widely used method of COVID-19 diagnostics is a reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay, to detect the presence of SARS-CoV-2 RNA in patient samples, typically from nasopharyngeal swabs. RNA extraction is a major bottleneck in current COVID-19 testing, in terms of turn-around, logistics, component availability and cost, which delays or completely precludes COVID-19 diagnostics in many settings. Efforts to simplify the current methods are important, as increased diagnostic availability and efficiency is expected to benefit patient care and infection control. Here, we describe methods to circumvent RNA extraction in COVID-19 testing by performing RT-qPCR directly on heat-inactivated subject samples as well as samples lysed with readily available detergents. Our data, including cross-comparisons with clinically diagnosed patient samples, suggest that direct RT-qPCR is a viable option to extraction-based COVID-19 diagnostics. We argue that significant savings in terms of time and cost can be achieved by embracing RNA-extraction-free protocols, that feeds directly into the established PCR-based testing pipeline. This could aid the expansion of COVID-19 testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported and funded by the SciLifeLab COVID-19 initiative, the Knut and Alice Wallenberg Foundation, the Swedish Research Council and the Ragnar Söderberg Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available.